Table 3.
Sensitivity analysis.
| Number of studies | Results [95% CI] | Heterogeneity | Effect measure | |||
|---|---|---|---|---|---|---|
| Fixed-effect model | Random-effect model | I 2 (%) | P value | |||
| Response rate | 18 | 1.55 [1.34, 1.79] | 1.47 [1.28, 1.68] | 0 | 0.80 | Risk ratio |
| Disease control rate | 18 | 1.28 [1.19, 1.37] | 1.25 [1.15, 1.35] | 29 | 0.12 | Risk ratio |
| Overall survival | 5 | 0.72 [0.61, 0.86] | 0.70 [0.58, 0.86] | 13 | 0.33 | Hazard ratio |
| KPS | 12 | 1.86 [1.53, 2.26] | 1.74 [1.43, 2.12] | 3 | 0.42 | Risk ratio |
| Decline of leucocyte count | 12 | 0.85 [0.79, 0.92] | 0.85 [0.75, 0.97] | 78 | <0.00001 | Risk ratio |
| VEGF | 4 | −1.32 [−1.59, −0.04] | −1.22 [−1.95, −0.48] | 85 | 0.0002 | SMD |
| Ratio of CD4/CD8 | 3 | 0.67 [0.38, 0.95] | 0.70 [0.08, 1.33] | 79 | 0.009 | SMD |